BDO has recently provided financial and tax due diligence services to AIM-listed specialty global pharmaceutical group, Clinigen Group PLC, in connection with their (up to) £100m acquisition of Link Healthcare group.
With three key operational hubs in Singapore, South Africa and Australia (with further local operations in Hong Kong, Japan and New Zealand), Link Healthcare is a specialist pharmaceutical and medical technology business. It offers a range of services including full commercial launch services, mature and discontinued product lifecycle management, comprehensive regulatory services, marketing and logistics. Further, it offers early market access programs (including sourcing of Named Patient Supply for over 200 essential medicines) and holds over 100 Marketing Authorisations in its local markets. The acquisition significantly strengthens Clinigen's position in the Asia, Africa and Australasia region. Clinigen is currently one of the top 10 companies on AIM (by market capitalisation).
The due diligence work was undertaken by an integrated international BDO team from the UK, Johannesburg, Sydney, Singapore and Tokyo, further demonstrating our specialist global capability.
“BDO were once again our trusted due diligence advisors through this transaction, providing invaluable, pragmatic advice and support throughout the process. They understand our business thoroughly having assisted us on a number of occasions in the past. I would not hesitate in recommending the Birmingham BDO Corporate Finance team.”
Robin Sibson, Chief Financial Officer, Clinigen Group PLC